These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33388397)

  • 1. Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome.
    Mohamed MO; Rashid M; Timmis A; Clarke S; Lawson C; Michos ED; Kwok CS; De Belder M; Valgimigli M; Mamas MA
    Int J Cardiol; 2021 Apr; 329():16-22. PubMed ID: 33388397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of bleeding and ischemic risk and their association with clinical outcomes in acute coronary syndrome.
    Mohamed MO; Kinnaird T; Anderson R; Rashid M; Martin GP; Freeman P; Kwok CS; Myint PK; Zaman AG; Mamas MA
    Int J Cardiol; 2019 Sep; 290():7-14. PubMed ID: 31133430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
    Chen Y; Yin T; Xi S; Zhang S; Yan H; Tang Y; Qian J; Chen J; Su X; Du Z; Wang L; Qin Q; Gao C; Zheng Y; Zhao X; Cheng X; Li Z; Zhang W; Chen H; Wang J; Yang Z; Li H; Liu H; Zhou X; Qu B; Xiang D; Guo Y; Wang L; Nie S; Fu G; Yang M; Cai S
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1194-1204. PubMed ID: 31112635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk scoring to guide antiplatelet therapy post-percutaneous coronary intervention for acute coronary syndrome results in improved clinical outcomes.
    Antoniou S; Colicchia M; Guttmann OP; Rathod KS; Wright P; Fhadil S; Knight CJ; Jain AK; Smith EJ; Mathur A; Weerackody R; Wragg A; Jones DA
    Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):283-289. PubMed ID: 29126112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.
    Bardají A; Leal M; Arrarte V; Garcia-Moll X; Pérez de Isla L; Bueno H
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27885830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial.
    Ono M; Kawashima H; Hara H; Gamal A; Wang R; Gao C; O'Leary N; Soliman O; Piek JJ; van Geuns RJ; Jüni P; Hamm CW; Valgimigli M; Vranckx P; Windecker S; Steg PG; Fox KA; Onuma Y; Serruys PW
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E513-E522. PubMed ID: 34000088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score.
    Bian L; Qiu M; Li Y; Xu X; Li J; Ma S; Qi Z; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():665-673. PubMed ID: 31957965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
    Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
    Chandrasekhar J; Baber U; Sartori S; Faggioni M; Aquino M; Kini A; Weintraub W; Rao S; Kapadia S; Weiss S; Strauss C; Toma C; Muhlestein B; DeFranco A; Effron M; Keller S; Baker B; Pocock S; Henry T; Mehran R
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):629-637. PubMed ID: 27152497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients.
    Wan J; Wang P; Zhou P; Liu S; Wang D; Kan J; Hou J; Zuo L; Ma S; Yang Y
    Cell Physiol Biochem; 2018; 50(3):1164-1177. PubMed ID: 30355936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive value of the GRACE discharge score on the long-term out-of-hospital coronary thrombotic events after implantation of drug-eluting stents].
    Zhao XY; Li JX; Tang XF; Xian Y; Xu JJ; Song Y; Jiang L; Xu LJ; Chen J; Zhang Y; Song L; Gao LJ; Gao Z; Zhang J; Wu Y; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Mar; 46(3):187-191. PubMed ID: 29562422
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk stratification in acute coronary syndrome: Evaluation of the GRACE and CRUSADE scores in the setting of a tertiary care centre.
    Tscherny K; Kienbacher C; Fuhrmann V; van Tulder R; Schreiber W; Herkner H; Roth D
    Int J Clin Pract; 2020 Feb; 74(2):e13444. PubMed ID: 31667929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents.
    Jang JY; Lee BK; Kim JS; Shin DH; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Park KW; Gwon HC; Kim HS; Kwon HM; Jang Y
    Circ J; 2020 Jan; 84(2):161-168. PubMed ID: 31839621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
    Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI.
    Xi S; Zhou S; Wang X; Liu J; Qin L; Liu J; Yin T; Chen Y
    Thromb Haemost; 2017 Nov; 117(11):2186-2193. PubMed ID: 29044298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
    Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.